Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $50
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $48 to $50.
Citigroup analyst Geoff Meacham maintains Royalty Pharma (NASDAQ:RPRX) with a Buy and raises the price target from $48 to $50.